<DOC>
	<DOCNO>NCT01300572</DOCNO>
	<brief_summary>This phase I trial study side effect maximum tolerate dose yttrium Y 90 anti-cluster differentiation 45 ( CD45 ) monoclonal antibody BC8 ( 90Y-BC8 ) follow donor stem cell transplant treat patient acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , myelodysplastic syndrome ( MDS ) likely come back spread . Giving chemotherapy drug , fludarabine phosphate ( FLU ) , total-body irradiation ( TBI ) donor peripheral blood stem cell ( PBSC ) bone marrow transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . Radiolabeled monoclonal antibody , 90Y-BC8 , find cancer cell carry cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving FLU , 90Y-BC8 , TBI transplant together cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed Donor Stem Cell Transplant Treating Patients With High-Risk Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) radiation deliver via 90Y-DOTA-BC8 ( 90Y-BC8 ) combine FLU 2 Gy TBI preparative regimen patient age &gt; = 18 advanced AML , ALL , high-risk MDS . SECONDARY OBJECTIVES : I . To determine disease response duration remission . II . To determine rate engraftment donor chimerism result combine preparative regimen , correlate level donor chimerism estimate radiation dos deliver hematopoietic tissue via antibody . OUTLINE : PREPARATIVE REGIMEN : Patients receive 90Y-BC8 via central line approximately day -12 FLU intravenously ( IV ) 30 minute day -4 -2 . TRANSPLANTATION : Patients undergo TBI follow allogeneic PBSC bone marrow transplant day 0 . GRAFT-VS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients receive mycophenolate mofetil orally ( PO ) IV every 12 hour day 0-27 ( patient relate donor ) every 8 hour day 0-40 taper day 96 ( patient unrelated donor ) . Patients also receive cyclosporine PO IV every 12 hour day -3 56 ( patient relate donor ) 100 ( patient unrelated donor ) taper day 180 . After completion study treatment , patient follow 6 , 9 , 12 , 18 , 24 month , annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must advance AML , ALL highrisk MDS meet one follow description : AML ALL beyond first remission ( i.e. , relapse least one time achieve remission response treatment regimen ) AML ALL represent primary refractory disease ( i.e. , fail achieve remission time follow one prior treatment regimen ) AML evolve myelodysplastic myeloproliferative syndrome ; MDS express refractory anemia excess blast ( RAEB ) chronic myelomonocytic leukemia ( CMML ) FrenchAmericanBritish ( FAB ) criterion Patients remission must CD45expressing leukemic blast ; patient remission require phenotyping may leukemia previously document CD45 negative ( remission patient , virtually antibody bind nonmalignant cell make &gt; = 95 % nucleated cell marrow ) Patients circulate blast count le 10,000/mm^3 ( control hydroxyurea similar agent allow ) Patients must estimate creatinine clearance great 50/ml per minute ( serum creatinine value must within 28 day prior registration ) Bilirubin &lt; 2 time upper limit normal Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &lt; 2 time upper limit normal Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Karnofsky &gt; = 70 Patients must expect survival &gt; 60 day must free active infection Patients must human leukocyte antigen ( HLA ) identical sibling donor HLAmatched unrelated donor meet standard Seattle Cancer Care Alliance ( SCCA ) and/or National Marrow Donor Program ( NMDP ) donor center criterion PBSC bone marrow donation , follow : Related donor : relate patient genotypically phenotypically identical HLAA , B , C , DRB1 DQB1 ; phenotypic identity must confirm highresolution type Unrelated donor : Matched HLAA , B , C , DRB1 DQB1 high resolution typing ; OR mismatch single allele without antigen mismatch HLAA , B C define high resolution type otherwise match HLAA , B , C , DRB1 DQB1 high resolution type Doors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient hematopoietic cell transplant ( HCT ) ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result ; positive antidonor cytotoxic crossmatch absolute donor exclusion Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch ; i.e. , patient A*0101 donor A*0102 , type mismatch allow DONOR : Donors must meet HLA match criterion standard SCCA and/or National Marrow Donor Program ( NMDP ) donor center criterion PBSC bone marrow donation Circulating human antimouse antibody ( HAMA ) Prior radiation maximally tolerated level critical normal organ , &gt; 20 Gy prior radiation large area bone marrow ( e.g. , external radiation therapy whole pelvis ) Patients may symptomatic coronary artery disease may cardiac medication antiarrhythmic inotropic effect Left ventricular ejection fraction &lt; 35 % Corrected diffusion lung capacity carbon monoxide ( DLCO ) &lt; 35 % receive supplemental continuous oxygen Liver abnormality : fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis , symptomatic biliary disease Patients know seropositive human immunodeficiency virus ( HIV ) Perceived inability tolerate diagnostic therapeutic procedure Active central nervous system ( CNS ) leukemia time treatment Women childbearing potential pregnant ( betahuman chorionic gonadotropin positive [ HCG+ ] ) breast feed Fertile men woman unwilling use contraceptive 12 month posttransplant Inability understand give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>